Cite
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.
MLA
Douthwaite, Julie, et al. “A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.” Journal of Immunology (Baltimore, Md. : 1950), vol. 198, no. 1, Jan. 2017, pp. 528–37. EBSCOhost, https://doi.org/10.4049/jimmunol.1600682.
APA
Douthwaite, J., Moisan, J., Privezentzev, C., Soskic, B., Sabbah, S., Cohen, S., Collinson, A., England, E., Huntington, C., Kemp, B., Zhuang, L., Hudak, S., Rees, D. G., Goldberg, D., Barton, C., Chang, L., Vainshtein, I., Liang, M., Iciek, L., … Jermutus, L. (2017). A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding. Journal of Immunology (Baltimore, Md. : 1950), 198(1), 528–537. https://doi.org/10.4049/jimmunol.1600682
Chicago
Douthwaite, Julie, Jacques Moisan, Cyril Privezentzev, Blagoje Soskic, Shereen Sabbah, Suzanne Cohen, Andie Collinson, et al. 2017. “A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.” Journal of Immunology (Baltimore, Md. : 1950) 198 (1): 528–37. doi:10.4049/jimmunol.1600682.